{"id":"W4403119976","doi":"10.1200/jco.24.00055","title":"INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; McGill University Health Centre","funders":"","keywords":"Regorafenib; Medicine; Placebo; Internal medicine; Hazard ratio; Clinical endpoint; Cohort; Refractory (planetary science); Progression-free survival; Oncology; Quality of life (healthcare); Gastroenterology; Cancer; Surgery; Confidence interval; Overall survival; Clinical trial; Colorectal cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004933339,0.001079606,0.001956003,0.0003331304,0.0003658847,0.001073588,0.000761725,0.0008661828,0.003178715],"category_scores_gemma":[0.002085702,0.0003961652,0.003059832,0.0007198327,0.0004467904,0.0004341403,0.0005663907,0.001524452,0.000469027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006026803,"about_ca_system_score_gemma":0.001833969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001700475,"about_ca_topic_score_gemma":0.004128071,"domain_scores_codex":[0.9990379,0.0005806707,0.00006520594,0.0001171587,0.0001300659,0.00006906116],"domain_scores_gemma":[0.9991438,0.0001732227,0.0002979949,0.00009933565,0.00009844406,0.000187092],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8198643,0.007044549,0.02576192,0.006099212,0.01533911,0.0003474136,0.0001741535,0.002545228,0.02059998,0.0008400594,0.009350172,0.09203392],"study_design_scores_gemma":[0.7610161,0.1502838,0.05006495,0.0007768401,0.01345904,0.0004421809,0.0000972519,0.001286903,0.003261015,0.000634921,0.01861665,0.00006022681],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8802303,0.06122482,0.003639794,0.001940764,0.000806245,0.02303151,0.01116283,0.0002220191,0.01774175],"genre_scores_gemma":[0.9459856,0.015037,0.004474378,0.003478291,0.001054426,0.01475289,0.008886147,0.00005770914,0.006273571],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004933339,"threshold_uncertainty_score":0.02609032,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1541743995025599,"score_gpt":0.541799323162396,"score_spread":0.387624923659836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}